% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Seiler:305740,
      author       = {I. Seiler and S. Schäfer and C. von Wachter and P.
                      Balermpas and M. Slavik and P. Burkon and J. Meents and L.
                      Kästner and F. Lohaus$^*$ and J. Willner and A. S. Schunn
                      and S. Drabke and K. Klischies and O. Wittenstein and P.
                      Bank and R. Partl and J.-A. Müller and A. Gawish and A.
                      Grün and A. Baehr and M. Trommer and A. Glasmacher and T.
                      Mader and R. Holy and Y. Dzierma and F. Ehret$^*$ and A.
                      Rühle and M. Guckenberger and C. Moustakis and T. Brunner
                      and O. Blanck and J. Boda-Heggemann and N. H. Nicolay and F.
                      Nägler},
      title        = {{I}mpact of target volume and dose concepts on the outcomes
                      of prostate cancer patients treated with stereotactic body
                      radiotherapy for spinal metastases - a {E}uropean
                      multicenter cohort study.},
      journal      = {Radiotherapy and oncology},
      volume       = {214},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-02363},
      pages        = {111276},
      year         = {2026},
      note         = {Volume 214, January 2026, 111276},
      abstract     = {The importance of metastasis-directed radiotherapy is
                      increasing in the management of oligometastatic prostate
                      cancer. We evaluated different target volume and dose
                      concepts for stereotactic body radiotherapy (SBRT) of spine
                      bone metastases (BoM) from prostate cancer in a large
                      European cohort.Data of prostate cancer patients receiving
                      SBRT for spine BoM between 2010 and 2024 at 19 European
                      cancer centers were retrospectively collected. Treatment
                      volumes and dose concepts were analyzed regarding their
                      impact on overall survival (OS), freedom from local
                      recurrence (FFLR), biochemical recurrence-free survival
                      (BRFS), and progression-free survival (PFS).With a median
                      follow-up of 25.1 months (range: 1.4-77.2), 213 patients
                      with 283 spine BoM were evaluated. 1-/3-year PFS with
                      simultaneously integrated boost (SIB) were 85.7 $\%/73.9$
                      $\%$ (BED4 [Biologically effective dose with α/β-ratio = 4
                      Gy] ≥ 100 Gy) and for non-SIB concepts 81.2 $\%/45.5$ $\%$
                      (BED4 ≥ 100 Gy), respectively. 1-/3-year BRFS for
                      SIB-treated BoM amounted to 81.7 $\%/68.4$ $\%$ (BED4 ≥
                      100 Gy) and for non-SIB 78.3 $\%/43.6$ $\%$ (BED4 ≥ 100
                      Gy). OS was not significantly different for the evaluated
                      dose and target volume concepts. For FFLR a significant
                      difference was observed favoring BED4 ≥ 100 Gy. In
                      multivariable analysis, following factors were positively
                      associated with both PFS and BRFS: BED4 for GTVmean dose and
                      SIB concept. Adverse events were very low, with fracture
                      rates of 2.2 $\%.This$ multicenter cohort analysis showed
                      that SBRT of spine BoM from prostate cancer is an effective
                      and well-tolerated treatment. Both BED and usage of a SIB
                      concept were associated with improved PFS and BRFS.
                      Prospective studies are needed to confirm these findings and
                      further standardize SBRT concepts.},
      keywords     = {Bone metastases (Other) / Dose concept (Other) /
                      Metastasis-Directed therapy (MDT) (Other) / Prostate cancer
                      (Other) / Spine metastases (Other) / Stereotactic
                      radiotherapy (Other) / Target concept (Other)},
      cin          = {DD01 / BE01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331 / I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41213475},
      doi          = {10.1016/j.radonc.2025.111276},
      url          = {https://inrepo02.dkfz.de/record/305740},
}